Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:35 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Prednisolone Versus Colchicine for Acute Gout in Primary Care
NCT05698680 · University Medicine Greifswald · PHASE4 · terminated · last registry update 2026-05-15 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was terminated due to an inability to reach the planned sample size, despite efforts to enhance recruitment.” | – | Registry record, University Medicine Greifswald |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TUBB4B within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-05Phase 3 first posted: Merck Sharp & Dohme LLC, MK-1045 + Zilovertamab vedotin (NCT07917754)
- 2026-11-02Phase 3 first posted: AstraZeneca, Surovatamig + Rituximab (NCT07911553)
- 2026-10-29Results posted on the registry: City of Hope Medical Center, Bleomycin + Brentuximab Vedotin (NCT03712202)
- 2026-10-28Results posted on the registry: Washington University School of Medicine, Mosunetuzumab + Polatuzumab vedotin (NCT05410418)
- 2026-10-21Results posted on the registry: Incyte Biosciences Japan GK, tafasitamab + lenalidomide (NCT04661007)
- 2026-10-19Phase 3 first posted: CSPC Megalith Biopharmaceutical Co.,Ltd., Enter a brief, descriptive name for the intervention. Use a non-proprietary (generic) name, if available. SYS6043 + Investigator's Choice of Chemotherapy (paclitaxel,nab paclitaxel,capecitabine,eribulin,carboplatin) (NCT07879911)
- 2026-10-16Also stopped (terminated): Henan Cancer Hospital, Eribulin and Tucidinostat (NCT05335473)
- 2026-10-15Also stopped (terminated): Spanish Breast Cancer Research Group, Trastuzumab + Alpelisib (NCT05063786)
- 2026-10-05Also stopped (terminated): Children's Oncology Group, Cyclophosphamide + Doxorubicin Hydrochloride (NCT06820957)
- 2026-10-01Phase 3 first posted: ECOG-ACRIN Cancer Research Group, Abiraterone Acetate + Cabazitaxel (NCT07852195)
- 2026-09-29Also stopped (suspended): University of Washington, Asparaginase Erwinia chrysanthemi + Cyclophosphamide (NCT06738368)
- 2026-09-24Also stopped (withdrawn): Case Comprehensive Cancer Center, Neoadjuvant Chemotherapy + Adjuvant systemic therapy (NCT06290687)
- 2026-09-21Also stopped (terminated): Institut Claudius Regaud, Zolinza (vorinostat), vinorelbine (NCT00801151)
- 2026-09-18Also stopped (terminated): Pusan National University Yangsan Hospital, dose dense MVAC with pegylated GCSF (NCT04047693)
- 2026-09-17Phase 3 first posted: Vivace Therapeutics, Inc, VT3989 + gemcitabine (NCT07824986)
- 2026-09-17Also stopped (terminated): Centre Oscar Lambret, Vinblastine + Cyclophosphamide (NCT03585465)
- 2026-09-15Results posted on the registry: Academic and Community Cancer Research United, Brentuximab Vedotin + Dacarbazine (NCT03233347)
- 2026-09-14Also stopped (terminated): Astellas Pharma Global Development, Inc., Enfortumab vedotin (NCT05014139)
- 2026-09-11Phase 3 first posted: Summit Therapeutics, Ivonescimab Dose 1 + enfortumab vedotin (EV) (NCT07815665)
- 2026-09-09Results posted on the registry: National Cancer Institute (NCI), Eribulin Mesylate (NCT00365157)
- 2026-09-01Also stopped (suspended): CStone Pharmaceuticals, CS5001 + Rituximab (NCT05279300)
- 2026-08-18Results posted on the registry: Hoffmann-La Roche, Glofitamab + Tocilizumab (NCT04980222)
- 2026-08-11Results posted on the registry: Wake Forest University Health Sciences, Cyclophosphamide + Doxorubicin Hydrochloride (NCT03505762)
- 2026-08-04Results posted on the registry: Mirati Therapeutics Inc., Sitravatinib + Nivolumab (NCT04887870)
- 2026-08-03Results posted on the registry: Hoffmann-La Roche, Atezolizumab + Enfortumab Vedotin (NCT03869190)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision